Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor.
Using C3H/He JCr mice bearing the syngeneic MBT-2 bladder tumor, it was found that cyclophosphamide (CYC 100 mg/kg i.p.) treatment, 1 day before and 2 weeks after surgery, followed by postoperative autologous tumor vaccine immunization can be an effective adjuvant anticancer therapy. The short-term exogeneous addition of low dose Il-2 administration to the protocol provided no further benefit. Suppression of tumor growth was observed in a classical Winn assay when splenocytes were obtained on day 23 from mice receiving this effective adjuvant therapy with surgery on day 8. Splenocytes from tumor-bearing mice (TBM) treated with CYC were augmented in terms of their proliferative response to concanavalin A during the first 2 weeks after CYC treatment. Studies using 3-day TBM established that significant suppression of tumor growth and prolonged survivals were dependent upon CYC treatment being combined with tumor vaccine and/or interleukin-2; single agent treatments were ineffective.
Tzai
T S
TS
Department of Urology, Medical College, National Cheng Kung University, Tainan, Taiwan, Republic of China.
Lin
J S
JS
Chow
N H
NH
D000818:Animals; D002455:Cell Division; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D007167:Immunotherapy; D016233:Immunotherapy, Active; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D014407:Tumor Cells, Cultured / Q000166:cytology; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D007376:Interleukin-2; D003520:Cyclophosphamide